focus -WSS

focus

author：leisure time 2025-10-04 04:00:07 - browse：31556

WASHINGTON — Grail is aggressively lobbying to get Medicare to pay for its cancer-screening test Galleri — but experts tell STAT that the company has a far more complicated path to that end than the makers of most medicines or medical devices.

Grail’s controversial blood test Galleri screens for multiple cancers. The Food and Drug Administration has not yet approved it, so Medicare hasn’t had to make a decision on whether to cover it or not. Right now, most people pay for it out of pocket. It runs about $950.

In general, Medicare covers FDA-approved medicines and medical devices that help diagnose or treat disease or injury. But there’s a catch for Grail: Medicare doesn’t cover tests that simply screen healthy people, as Galleri does.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： As demand for Covid shots wanes, Moderna seeks its next success

explore

WSS

Brain injuries and the importance of a second opinion

Coloradans with cystic fibrosis could lose access to Trikafta

Live blog: Hearing on CRISPR

Prime Medicine says its gene editing passes test in monkeys

Infant mortality in U.S. rose last year for first time in decades: CDC

Tori Bowie and the unacceptable rates of Black maternal death

hotspot

focus

focus

Activists slam private health insurers over coverage restrictions

Life sciences investors close nearly $6 billion in new funds

Duchenne breakthrough therapy leaves behind pioneering families

Gene therapy’s promise and the high cost of hope

How to save PrEP access — and even expand it

Medical leaders decry Supreme Court decision on affirmative action

Walensky prepares to leave CDC — and Congress — behind

Humans aren't the only ones with an imagination. Rats have it too

How one medical school became remarkably diverse

Inari Medical to buy amputation prevention company LimFlow

Wikipedia

Explaining an after

23andMe had bad news about my health. I wish a person had delivered it

After Sarepta trial failure, Duchenne families brace for more debate

How to convince healthy people to buy insurance

In Memoriam: Notable people who died in 2023

Travis Kelce and the trap of celebrity vaccine endorsements

leisure time

entertainment

explore

Wikipedia